Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.

In our small study, dasatinib-related PE was associated with low-grade pericardial effusion but no ascites. There are hypothetical explanations of this phenomenon including the simultaneous activation/inhibition of kinases; however, more research needs to be performed on this topic.